In one paragraphArticle in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Anastasia RybinaDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Anna MedvedevaDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Roman ZelchanDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Olga BraginaDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Liubov TashirevaDepartment of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.ORCID 0000-0003-2061-8417 Maria LarkinaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0003-1176-2441 Ruslan VarvashenyaDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.ORCID 0009-0002-4282-3198 Nadejda LushnikovaDepartment of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Panagiotis KanellopoulosDepartment of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.ORCID 0000-0002-0617-3936 Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden.ORCID 0000-0002-6122-1734 Vladimir ChernovDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Funding
Cancer Society (Cancerfonden) 23 2645 PjF 01HProstatacancerfonden PKSwedish Cancer Society (Cancerfonden) 24 3523 PjSwedish Research Council (Vetenskapsrådet) 2022-00556Swedish Research Council (Vetenskapsrådet) 2023-02158
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
GRPRmolecular imagingprostate cancerSPECTTc-99m
Identifiers
PMID41155959
PMCPMC12567192
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390